Crossroads Clinical Research LLC

1. Merck Sharp & Dohme Corporation $2,460,294 395 payments
2. Eli Lilly and Company $550,114 8 payments
3. Pfizer Inc. $309,618 42 payments
4. Evofem Biosciences, Inc. $37,144 15 payments
5. Novo Nordisk AS $14,110 6 payments
6. Boehringer Ingelheim Pharmaceuticals, Inc. $6,475 2 payments
7. Esperion Therapeutics, Inc. $3,785 9 payments
8. AbbVie, Inc. $2,852 3 payments
9. Akebia Therapeutics Inc $2,083 3 payments

1. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $896,684 18 payments
2. V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $870,452 26 payments
3. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $420,090 5 payments
4. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $412,647 5 payments
5. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $276,863 23 payments
6. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $130,023 3 payments
7. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $77,224 303 payments
8. A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent $71,112 1 payment
9. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 Laboratory-confirmed SARS-CoV-2 Infection With Symptoms in Adults Residing With a Person With COVID-19 $64,627 5 payments
10. A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent $56,783 1 payment

1. Professional salary support $34,014 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.